Per https://t.co/C8jZi2nVDn, $PFE anticipates (as of May 20 study update) starting #AFFINE pivotal Phase 3 trial of $SGMO SB-525 /PF-07055480 on July 15. 
https://t.co/guP49edR2O
https://t.co/HBuBTqKpV8